Correction to Lancet Gastroenterol Hepatol 2024; 9: 705–17

Abstract

Kang Y-K, Terashima M, Kim Y-W, et al. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2024; 9: 705–17—In this Article, the penultimate sentence of the Findings section of the Summary should read: “Discontinuation due to treatment-related adverse events was more frequent in the nivolumab plus chemotherapy group (34 [9%] of 371 patients) than the placebo plus chemotherapy group (13 [4%] of 374 patients).” Reasons for treatment discontinuation have been clarified in figure 1 and some rounding errors have been corrected in tables 1 and 2. In figure 2B, the CI for the hazard ratio has been corrected to read “95% CI”. The third sentence of the second paragraph of the Results section should read: “339 (90%) of 377 patients in the nivolumab group and 338 (89%) of 378 patients in the placebo group resided in Japan or South Korea.” The third paragraph of the Results section has been updated to read “Overall, 495 (66%) of 755 patients (228 [60%] of 377 in the nivolumab plus chemotherapy group; 267 [71%] of 378 in the placebo plus chemotherapy group) completed the prespecified adjuvant therapy and 128 (17%) of 755 patients (75 [20%] of those in the nivolumab plus chemotherapy group; 53 [14%] of those in the placebo plus chemotherapy group) discontinued both nivolumab and chemotherapy or placebo and chemotherapy (figure 1). 18 (24%) of 75 patients discontinued both components of therapy in the nivolumab plus chemotherapy group solely due to unacceptable toxicity, as did five (9%) of 53 in the placebo plus chemotherapy group.” The start of the fifth line of the ninth paragraph of the Results section has been revised to state “Similarly, discontinuation due to treatment-related adverse events was…”. In table 3, the number of patients in the placebo plus chemotherapy group who had grade 3 diarrhoea has been corrected to read “13 (3%)”. Details of deaths in the trial have been updated; the final two sentences of the Results section has been replaced with: “There was one death (subarachnoid haemorrhage) in the placebo plus chemotherapy group and two (asphyxia; pneumonitis) in the nivolumab plus chemotherapy group. Only the death due to pneumonitis in the nivolumab plus chemotherapy group was considered to be related to treatment.” These corrections have been made as of March 12, 2025.